TrialJournal of hematology & oncology2025

Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab.

Nicholas J Short et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.